{"url_path":"/sec/tsha/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-276738-index.html","accession_number":"0001193125-26-276738","cik":"0001806310","ticker":"TSHA","issuer_name":"Taysha Gene Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-276738-index.html","primary_entity_key":"0001806310","primary_entity_name":"Taysha Gene Therapies, Inc."},"word_count":49,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nClinical and Regulatory Update Presentation\n\nOn June 22, 2026, the Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K."}